This series features KU Medical Center's nationally recognized experts speaking about emerging issues. Conveniently scheduled on Tuesdays from 12:00 Noon - 1:00 p.m. and without charge. Emerging Trends is designed to inspire faculty, staff, students and others to incorporate state-of-the-art knowledge in their clinical and organizational practices. Registration is on-site only. Seating is on a space-available basis. Nurses and physicians can earn contact hours.
All sessions are at KU Medical Center, 3901 Rainbow Blvd., Kansas City, Kan. See the session for the room. A campus map is available at: http://www.kumc.edu/Pulse/map.html and paid parking is available in the Olathe and Cambridge Parking Facilities. Bring your own lunch, and join in the discussion about these exciting new trends.
Sponsored by KU HealthPartners, Inc. and the University of Kansas School of Nursing. Co-sponsored by Health Policy & Management, School of Medicine, University of Kansas Medical Center.
Contact: Mary L. Gambino, (913) 588-1695 or mgambino@kumc.edu
If you would like to receive e-mail updates for these programs, please send your request to mgambino@kumc.edu
For continuing education information: Click Here
There are major health and economic consequences of obesity. While weight loss interventions are often effective for the short-term, many individuals struggle with maintaining their weight loss over time. The purpose of this session is to help participants better understand differences in outcomes of weight loss interventions and stimulate new ideas regarding how to help treatment resistant obese patients. By the end of this program, participants will be able to:
|
Reference: Lenard, N. R., & Berthoud, H. (2008). Central and peripheral regulation of food intake and |
Date: |
Tuesday, November 17, 2009 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
Cary Savage, PhD, Director, Functional MRI, Hoglund Brain Imaging Center |
| Dr. Savage received his Ph.D. in clinical psychology from Oklahoma State University. He completed an internship in clinical psychology and postdoctoral fellowships in neuropsychology and functional neuroimaging at the Massachusetts General Hospital (MGH)/Harvard Medical School. He remained on the faculty of MGH and served as an Assistant Professor in the Department of Psychiatry at Harvard Medical School and the Director of Cognitive Neuroscience in the Department of Psychiatry at MGH. Dr. Savage also served as Director of Research and Training in the Division of Behavioral and Mental Health at Spaulding Rehabilitation Hospital. He was the founding Director of the Neuropsychology track in the APA-accredited Internship in Clinical Psychology at MGH. Dr. Savage moved to Kansas City in 2003 and now serves as Director of Functional MRI in the HBIC and as a Professor of Psychiatry and Behavioral Sciences at KUMC. Dr. Savage’s research is funded by the National Institutes of Health (NIH) and private foundations. His research focuses on the roles of prefrontal cortex and limbic system in memory and motivational processes, and how these networks are disrupted in psychiatric and neurologic conditions. Dr. Savage has published over 75 original research and review articles. He serves on the Editorial Board of the Journal of Geriatric Psychiatry and Neurology. |
For a protein to play its intended physiological role in the cell it must achieve its native configuration. It has been determined that the mitochondrial DNA, important in this process, encode only 13 of the more than 1000 different proteins present in the mitochondria. The remaining proteins are encoded by the nuclear genome, transcribed in the nucleus, translated in the cytoplasm and imported into the mitochondrion, where they fold to their native structure. Understanding these processes at the molecular level is of the utmost importance because alterations in protein tranlsocation cause disease. The main goals of Dr. Artigues' research are to understand; (a) the molecular basis for the distinct folding behavior of these homologous proteins, and (b) to elucidate the mechanisms for the differences observed in their interactions with the cellular machineries in charge of protein sorting, import and folding.
Date: |
Tuesday, December 15, 2009 |
Time: |
Noon - 1:00 p.m. |
Location: |
|
Fee: |
Free |
Faculty: |
Antonio Artigues, PhD, Research Assistant Professor, Director of the Mass Spectrometry Laboratory, Biochemistry and Molecular Biology |
| Antonio Artigues, PhD, received his BS and MS from the University of Navarre and his PhD from the University of the Balearic Islands, Spain. He also completed a postodoctoral fellowship at Virginia Commonwealth University and a fellowship at the University of Alicante. He was a research instructor, supervisor of the Macromolecular Analysis Core Facilities, research assistant professor, and deputy direcotr for research development at the University of Missouri-Kansas City prior to coming to the University of Kansas Medical Center in 2004. Dr. Artigues' research areas of interest include proteomics, protein-protein interactions, enzyme structure and relationship of enzyme structure to function, protein folding, and mechanisms of protein transport across membranes. |
Autism and autism spectrum disorders (ASD) are common with recent studies reporting an increase in the prevalence of autism disorders. It is unknown whether this increase is due to better diagnosis or is an actual increase. ASD is now reported to have a prevalence of about 1 in 100, making this disability more common than childhood cancer, blindness, and Down's syndrome. ASD is four times more frequent in males than in females. ASD includes a number of lifelong neurodevelopmental disorders, including autistic disorder, Asperger syndrome, and pervasive developmental disorder, not otherwise specified. Symptoms of ASD include significant social, communication, and behavioral limitations. Additionally, children diagnosed with ASD have significant comorbidities, with more than 500,000 children in the United States having costly health care needs.
Susceptibility to autism or ASD is clearly attributable to genetic factors with heritability estimates greater than 90%. Genome-wide scans have shown the involvement of over a dozen chromosomes and greater than 20 genes reported. Autism is frequently seen in tuberous sclerosis and fragile X syndrome, but these conditions account for only a small proportion of affected individuals. Diagnosable medical conditions, chromosome abnormalities and known single gene conditions account for less than 10% of cases; however, the use of newer genetic technology with chromosomal microarray hybridization will increase this percentage in future studies.
Progress is being made in understanding the etiology and pathogenesis of autism with genetics playing a major role. The purpose of this presentation is to review autism, present a diagnostic approach and discuss new and emerging information about the causes of autism and how this may impact on care and evaluation by healthcare professionals.
At the completion of this program, participants should be able to:
Date: |
Tuesday, January 19, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
Merlin G. Butler, MD, PhD, FFACMG |
| Dr. Butler received his M.D. degree from the University of Nebraska in 1978 and his Ph.D. degree in Medical Genetics from Indiana University in 1984. He completed an American Board of Medical Genetics accredited fellowship in Medical Genetics from 1980 to 1984 and became a Diplomate of the American Board of Medical Genetics in 1984. He is board-certified in Clinical Genetics and Clinical Cytogenetics. He became a Founding Fellow of the American College of Medical Genetics (ACMG) in 1993 and elected to serve a five-year term on the ACMG/CAP Cytogenetics Resource Committee in 1993. This committee oversees accreditation and proficiency testing of Cytogenetics laboratories in North America. He is Chairperson of the Scientific Advisory Board of the Prader-Willi Syndrome Association (USA) and has held this position for ten years. He received the Lifetime Achievement Award from the Prader-Willi Syndrome Association (USA) in 2008. Dr. Butler received the Distinguished Service Award from Chadron State College, Chadron, Nebraska in 1986, and the Distinguished Alumni Award from Indiana University in 2007. He has been an active member of several professional organizations including NIH study sections, editorial boards for journals, and conducted extramurally funded research on Prader-Willi, Angelman and fragile X syndromes, the genetics of autism and obesity and delineation of genetic disorders. He was selected by “Consumers’ Research Council of America, Guide to America’s Top Physicians” in 2004 and 2008 and to the “Best Doctors in America” in 2007-2008 and 2009-2010. He has published over 350 research articles, multiple book chapters and recently edited two textbooks: 1) Management of Prader-Willi Syndrome, 3rd ed., Spring-Verlag Publishers (2006) and 2) Genetics of Developmental Disabilities, 1st ed., Taylor & Francis Publishers (2005).
Dr. Butler was last appointed Section Chief of Medical Genetics and Molecular Medicine at Children’s Mercy Hospital and Professor of Pediatrics, University of Missouri - Kansas City School of Medicine from 1998 to 2008. Previous to that, he was a tenured Associate Professor of Pediatrics and Pathology and Director of the Regional Genetics Program at Vanderbilt University, Nashville, Tennessee from 1984 to 1998. Currently, he is Professor of Psychiatry & Behavioral Sciences and Pediatrics, University of Kansas Medical Center, engaged in a clinical genetics practice of children and adults presenting for genetics services with emphasis on developmental disabilities, congenital anomalies, cytogenetic syndromes, Prader-Willi syndrome, early onset of morbid obesity and autism. He performs genetics consultations for the psychiatry department in patients presenting with developmental disabilities, autism and/or congenital anomalies. His research interests include the genetics of obesity with emphasis on Prader-Willi syndrome and autism, psychiatric and behavioral genetics and the delineation of rare and uncommon clinical genetics syndromes. |
|
References: |
|
Chemotherapeutic agents have been around for decades, but most are fraught with significant side effects, such as nausea, hair loss, weight loss, immunosuppression, and for survivors an increase in the likelihood of another type of cancer years after the first occurrence. Promising research is now underway to create drugs that attack cancer cells with much more specificity, without causing these side effects. In this program, Dr. Sittampalam will share what is emerging from the research that will soon, hopefully, be translated to practice.
At the completion of this program, participants should be able to discuss the emerging evidence on the identification and testing of chemotherapeutic agents that specifically target cancer cells.
Date: |
Tuesday, February 16, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
G. Sitta Sittampalam, PhD, Professor, Pharmacology, Toxicology and Therapeutics; Deputy Director, Office of Therapeutics, Discovery and Development; & Co-Leader, Drug Discovery and Experimental Therapeutics Research Program, University of Kansas Cancer Cente |
Sittampalam received his PhD in Analytical Chemistry from the University of Arizona in 1982. He joined KUMC in September 2007 to assist in overseeing a fully integrated drug discovery and development program through collaboration of researchers, industry partners, regulatory and technology transfer resources. Sitta Sittampalam, PhD brings over 23 years of pharmaceutical industry experience at Eli Lilly & Company to help lead the Office of Therapeutics, Discovery and Development. His exceptional experience and background in drug discovery and assay development helps to foster the University of Kansas Cancer Center’s (KUCC) effort to attain its goal of being the number one academic generator of oncology drugs. Sittampalam joined Eli Lilly & Company in 1984, as a Senior Analytical Chemist in the Analytical Development Division. From 1989-2001, he assumed a series of senior positions in Biochemical Pharmacology to Bio Research Technologies Division at Lilly. In 2001, Sittampalam was named Head of the Lead Optimization Biology Laboratory where he oversaw lead generation and lead optimization and candidate selection efforts. In 2007, he resumed the role of Senior Research Advisor where he lead the Cell Technology group to develop an adult stem/progenitor cell-based screening platform for High Content Phenotypic Screening. In 2005, Sittampalam wrote and edited, “Assay Guidance Manual”, which is published and used by the National Institutes of Health as part of its RoadMap Program. His research interests are in developing innovative methods in quantitative biology, stem cell pharmacology and its applications in drug discovery. Of special interest is the integration of state-of-the-art cell high content imaging technologies and high throughput screening with engineered 3D tissues to identify and validate novel drug targets in cancer. Engineered 3D tumors grown from cancel cell lines will also serve as physiologically relevant in-vitro models for testing efficacy differences of existing anti-cancer agents, and the discovery of new more effective agents in pre-clinical models. Current research also involves isolation and characterization of circulating tumor cells (CTC) and cancer stem cells (CSC). They are believed to contribute to relapse and metastasis. We believe that a thorough understanding of the biology and pharmacology of these cells, and their response to known anti-tumor agents will advance the development of better agents to treat cancer. The detection of circulating tumor cells as diagnostic and prognostic biomarkers of metastasis is another area of interest. In addition, we are also developing methods to isolate and culture these rare cells for use in drug discovery applications. |
According to the National Heart, Lung, and Blood Institute's National Center on Sleep Disorders Research (NCSDR), about 70 million Americans suffer from sleep problems, and of those, nearly 60 percent have a chronic disorder. Each year, sleep disorders, sleep deprivation, and sleepiness add an estimated $15.9 billion to the national health care bill. Additional costs to society for related health problems, lost worker productivity, and accidents have not been calculated. Sleep disorders and disturbances of sleep comprise a broad range of problems, including sleep apnea, narcolepsy, insomnia, parasomnia, jet-lag syndrome, and disturbed biological and circadian rhythms.
Insomnia, for example, occurs in about one third of the adult population. Insomnia symptoms include difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, and nonrestorative sleep. It has been determined to be more common among women, middle-aged and older adults, shift workers, and people with medical or psychiatric disorders.
Join us to learn what sleep disorder research will do to improve patient care for this population.
Date: |
Tuesday, April 20, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
Bob Whitman, PhD, Director of Pulmonary Function Lab, Sleep Disorders Center, Cardiopulmonary Rehab., & Neuropsychology |
| Dr. Whitman, a certified sleep specialist, has worked with sleep disorders for more than 30 years. |
Overview:
By the end of this session, participants will be able to:
Date: |
Tuesday, September 21, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
Randolph Nudo , PhD, Professor, Molecular and Integrative Physiology; Director, Landon Center on Aging |
| Dr. Nudo received his PhD from Florida State University in 1985. The focus of his research is the brain's capacity for self-repair after damage utilizing both non-human primate and rodent models of stroke recovery to determine the neurophysiologic, neuroanatomic, biochemical and molecular bases for recovery. By tracking changes in the structure and function of motor areas of the cerebral cortex as a result of a focal vascular infarct, he is beginning to describe the cascade of events that give rise to the reorganized brain. He also studies novel forms of treatment in chronic stroke to enhance and accelerate the recovery process. These treatment interventions include physiotherapy, pharmacotherapy, or electrical stimulation therapy either alone or in combination. A goal is to use these interdisciplinary approaches to translate directly the information gained through brain plasticity research into effective clinical applications. |
By the end of this session, participants will be able to:
Date: |
Tuesday, October 19, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
Buddhadeb Dawn , MD, FACC, FAHA, Director, Cardiovascular Diseases and the Cardiovascular Research Institute |
Dawn is widely recognized for his research using adult bone marrow and cardiac stem cells to generate new, healthy tissue to repair the damaged heart after a heart attack. Prior to accepting his new position, Dr. Dawn served as a professor of medicine in the Division of Cardiology at the University of Louisville School of Medicine in Kentucky, the director of the Chest Pain Center at the University of Louisville Hospital, as well as a staff physician in several Louisville-area hospitals. His research has been funded by the National Institutes of Health as well as the American Heart Association. |
According to conventional wisdom, aging is inescapable and irreversible. Molecules, cells, and organs are all affected negatively by aging, and the incidence of certain diseases are also positively correlated to aging, e.g. arthritis, osteoporosis, cancer, dementia. While eternal youth has been long sought after, most of the early searching was for an external elixir or healing water, i.e., fountain of youth.
Many theories have been promulgated about aging, and have led to two major classifications. The first, programmed aging, suggests that every organism has control mechanisms within them that dictates elderliness and deterioration. The alternative classification suggests that aging is due to wear and tear, which is summative from things like radiation damage, chemical toxins, metal ions, free-radicals, etc. Damage from such substances affects genes, proteins, cell membranes, enzyme function, and other structures.
New evidence is beginning to shed light on aging that may in the near future impact patient care. The purpose of this session is provide health care professionals an update on the evidence and discuss the ongoing developments that health care professionals need to be aware of in their practice.
By the end of this session, the participant will be able to:
Date: |
Tuesday, November 16, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
B. T. Zhu , PhD, Professor, Pharmacology, Toxicology and Therapeutics |
| Dr. Zhu received his PhD in 1993 from the University of Texas Medical Branch. His research interests include:
1. Carcinogenic and anticancer actions of various endogenously-formed estrogen metabolites. 2. Physiological actions exerted by the endogenous estrogen metabolites. 3. Pharmacological actions of naturally-occurring compounds (such as dietary phenolic antioxidants and fatty acids) and their potential use as therapeutic agents in humans. |
May 5, 2009: The 2009 H2N1 Influenza Outbreak: What Every Healthcare Professional Needs to Know with Daniel Hinthorn, MD.
View presentation at: http://www2.kumc.edu/son/nce/Podcasts/H1N1_Update_050509.wmv
Resources:
©
The University of Kansas Medical Center
Obesity is a growing problem in the United States and other developed countries, yet little is understood regarding the role of the brain in regulating eating behavior and physical activity. Functional neuroimaging studies relating to obesity are beginning to appear in the research literature and clinical professionals could benefit from learning more about recent advances in the field.